Detalhe da pesquisa
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048786
2.
How I treat AML incorporating the updated classifications and guidelines.
Blood
; 141(23): 2813-2823, 2023 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758209
3.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
4.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311468
5.
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
Ann Hematol
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662203
6.
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Ann Hematol
; 103(1): 105-116, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036712
7.
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
J Oncol Pharm Pract
; : 10781552241238979, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38509812
8.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Cancer
; 129(2): 175-180, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36397669
9.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914241
10.
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Ann Hematol
; 102(11): 3049-3059, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37702821
11.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Ann Hematol
; 102(4): 749-754, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732419
12.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635381
13.
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
J Natl Compr Canc Netw
; 21(5): 522-528, 2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37037494
14.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
15.
Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Acta Haematol
; 146(4): 287-292, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166332
16.
Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.
Future Oncol
; 19(27): 1877-1889, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37750305
17.
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Future Oncol
; 19(9): 631-642, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37083373
18.
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Ann Hematol
; 101(3): 557-569, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981142
19.
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Ann Hematol
; 101(8): 1689-1701, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488900
20.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Am J Hematol
; 97(3): 322-328, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981560